Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Seizures elevate gliovascular unit Ca2+ and cause sustained vasoconstriction
Cam Ha T. Tran, Antis G. George, G. Campbell Teskey, Grant R. Gordon
Cam Ha T. Tran, Antis G. George, G. Campbell Teskey, Grant R. Gordon
View: Text | PDF
Research Article Neuroscience

Seizures elevate gliovascular unit Ca2+ and cause sustained vasoconstriction

  • Text
  • PDF
Abstract

Seizures can result in a severe hypoperfusion/hypoxic attack that causes postictal memory and behavioral impairments. However, neither postictal changes to microvasculature nor Ca2+ changes in key cell types controlling blood perfusion have been visualized in vivo, leaving essential components of the underlying cellular mechanisms unclear. Here, we use 2-photon microvascular and Ca2+ imaging in awake mice to show that seizures result in a robust vasoconstriction of cortical penetrating arterioles, which temporally mirrors the prolonged postictal hypoxia. The vascular effect was dependent on cyclooxygenase 2, as pretreatment with ibuprofen prevented postictal vasoconstriction. Moreover, seizures caused a rapid elevation in astrocyte endfoot Ca2+ that was confined to the seizure period, and vascular smooth muscle cells displayed a significant increase in Ca2+ both during and following seizures, lasting up to 75 minutes. Our data show enduring postictal vasoconstriction and temporal activities of 2 cell types within the neurovascular unit that are associated with seizure-induced hypoperfusion/hypoxia. These findings support prevention of this event may be a novel and tractable treatment strategy in patients with epilepsy who experience extended postseizure impairments.

Authors

Cam Ha T. Tran, Antis G. George, G. Campbell Teskey, Grant R. Gordon

×

Figure 4

COX-2 antagonism affects the secondary component of the MES evoked endfoot Ca2+ signal.

Options: View larger image (or click on image) Download as PowerPoint
COX-2 antagonism affects the secondary component of the MES evoked endfo...
(A) Summary time course of endfoot Ca2+ in the absence (red) or presence (purple) of ibuprofen in response to MES (N = 5). To limit photobleaching and/or photodamage, measurements were taken for 60 seconds every 300 seconds. Arrow and vertical dotted line indicate MES (0.2 second). Inset: Temporal close-up of percentage endfoot Ca2+ changes during the ictal and postictal period (5200 seconds) comparing vehicle (red) versus ibuprofen (purple). (B) Summary data comparing vehicle i.p. injection (red) with ibuprofen (purple) at a preictal (t test, t[3] = 0.99, P = 0.4), ictal peak (t test, t[3] = 1.57, P = 0.21), ictal plateau (t test, t[3] = 3.31, P = 0.04), and postictal time point (5200 seconds: [t test, t{3} = 0.77, P = 0.5]). (C) Summary data comparing the duration of the endfoot Ca2+ signal in vehicle (red) and ibuprofen (purple) during the ictal period (t test, t[3] = 3.9, P = 0.03). Data represent mean ± SEM. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts